Form 10-Q Dermata Therapeutics, For: Sep 30
Dermata Therapeutics, Inc. (DRMA)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
DRMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DRMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DRMA alerts
High impacting Dermata Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DRMA
News
- Dermata Therapeutics files to sell 1.94M shares of common stock for holders [Seeking Alpha]Seeking Alpha
- Dermata to Present on BioPub on January 31, 2025Accesswire
- Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq RulesAccesswire
- Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq RulesAccesswire
- Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)Accesswire
DRMA
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/13/25 - Form SCHEDULE
- 2/6/25 - Form EFFECT
- DRMA's page on the SEC website